<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208347</url>
  </required_header>
  <id_info>
    <org_study_id>DRAGON - IV</org_study_id>
    <secondary_id>Ahead-G208</secondary_id>
    <nct_id>NCT04208347</nct_id>
  </id_info>
  <brief_title>Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer</brief_title>
  <official_title>Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, safety and tolerability of
      chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery)
      or adjuvant (after surgery) treatment of previously untreated adults with gastric and
      gastroesophageal junction (GEJ) adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathological response(MPR)</measure>
    <time_frame>Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR)</measure>
    <time_frame>Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Margin-free (R0) resection rate</measure>
    <time_frame>Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Downstaging of N stage</measure>
    <time_frame>Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>Up to approximately 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib and Camrelizumab and S-1 and Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib and S-1 and Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1 and Oxaliplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib 250mg</intervention_name>
    <description>Apatinib 250mg</description>
    <arm_group_label>Apatinib and Camrelizumab and S-1 and Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200mg</description>
    <arm_group_label>Apatinib and Camrelizumab and S-1 and Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, Oxaliplatin</intervention_name>
    <description>S-1, Oxaliplatin, q3w</description>
    <arm_group_label>Apatinib and Camrelizumab and S-1 and Oxaliplatin</arm_group_label>
    <arm_group_label>Apatinib and S-1 and Oxaliplatin</arm_group_label>
    <arm_group_label>S-1 and Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib 500mg</intervention_name>
    <description>Apatinib 500mg</description>
    <arm_group_label>Apatinib and S-1 and Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has previously untreated localized gastric or GEJ adenocarcinoma as defined by
             T3-4N+M0;

          -  Plans to proceed to surgery following pre-operative chemotherapy.

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

          -  Has adequate organ function.

          -  Male participants of childbearing potential must agree to use an adequate method of
             contraception for the course of the study through 120 days after the last dose of
             therapy.

          -  Female participants of childbearing potential must be willing to use an adequate
             method of contraception for the course of the study through 120 days after the last
             dose of therapy.

          -  Has life expectancy of greater than 12 months.

        Exclusion Criteria:

          -  Uncontrolled hypertension ( systolic ≥140 mmHg or diastolic ≥90 mmHg despite
             antihypertensive therapy)

          -  Known hypersensitivity to any of the study drugs or excipients.

          -  Known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs,
             coagulation disorders, thrombocytopenia, etc.);

          -  Congenital or acquired immune deficiency (e.g. HIV infected)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenggang Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanan Zheng</last_name>
    <phone>+8613636404065</phone>
    <email>ianzyn@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen LI</last_name>
    <phone>+8613916632699</phone>
    <email>leedoctor@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanan Zheng</last_name>
      <phone>+8613636404065</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

